phrykt

Silo Pharma, Inc. (SILO): who owns it and who trades it

As of Nov 16, 2026, SILO insiders reported 6 purchases worth $7.7K in the last 12 months. The largest buyer was Eric Weisblum (CEO), with $7.7K. 2 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Silo Pharma

From the latest filings

Overall: more buying than selling. Insiders mostly bought. Famous investors was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Insider trades

In the last 12 months, SILO insiders reported $7.7K of open-market purchases and $0 of sales.

Purchases, 12 months
$7.7K
6 trades, 1 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
Dec 15, 2025
Filed Dec 16, 2025

Purchases and sales by month

$2.1K$2.1KDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Dec 15, 2025Eric WeisblumCEOPurchase2,500$0.42$1.1KForm 4
Dec 15, 2025Eric WeisblumCEOPurchase2,500$0.41$1KForm 4
Nov 21, 2025Eric WeisblumCEOPurchase1,000$0.37$370Form 4
Nov 20, 2025Eric WeisblumCEOPurchase1,000$0.37$370Form 4
Nov 19, 2025Eric WeisblumCEOPurchase4,500$0.41$1.8KForm 4
Nov 18, 2025Eric WeisblumCEOPurchase7,500$0.40$3KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Eric WeisblumChief Executive Officer, Director$7.7K–Dec 15, 2025
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

SILO short interest

Low short interest. 0.9% of SILO shares are sold short: about 1 share in 115. Over the last 12 reports the number of shares short went down 98%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 13,785 SILO shares were sold short, 0.9% of the shares outstanding, down 37.6% from the report before. At the average daily volume of 12,874 shares, buying them all back would take about 1.1 trading days (days to cover).

Shares short, % of all shares

0.87%May 15Oct 305.99%

Days to cover

1.1May 15Oct 306.3

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202613,7850.87%-38%12,8741.1
Oct 15, 202622,0781.39%-37%156,4981.0
Sep 30, 202634,8702.20%+20%76,3121.0
Sep 15, 202629,0721.83%-12%24,8641.2
Aug 31, 202633,2082.09%-60%206,1201.0
Aug 14, 202682,9485.22%-34%81,5061.0
Jul 31, 2026126,5490.89%-18%22,5125.6
Jul 15, 2026155,1101.09%+796%708,3971.0
Jun 30, 202617,3200.12%+3%83,3741.0
Jun 15, 202616,7900.12%-95%41,2471.0
May 29, 2026322,7952.28%-56%222,6021.4
May 15, 2026728,3735.14%-6%296,0722.5

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Silo Pharma company events

Silo Pharma filed 12 reports on Form 8-K in the last 12 months, 1 of them about an important change (listing). The latest was on Nov 6, 2026.

  1. Nov 6, 2026AgreementSilo Pharma, Inc. entered into securities purchase agreements with certain accredited investors for the issuance and sale in a private placement of (i) 136,005 shares of the Company’s common stock, par value $0.0001 per share at a purchase price of $1.50 per Share and (ii) pre-funded warrants to… Filing
  2. Oct 14, 2026AgreementSilo Pharma, Inc. entered into an asset purchase agreement with Larry King. Filing
  3. Oct 2, 2026AgreementSilo Pharma, Inc. entered into an asset purchase agreement with Norsight Consulting Inc., an Arkansas corporation. Filing
  4. Aug 19, 2026AgreementSilo Pharma, Inc. entered into an asset purchase agreement with Parkview Consulting LLC. Filing
  5. Aug 17, 2026VoteReported shareholder vote results. Filing
  6. Jul 13, 2026AgreementSilo Pharma, Inc. entered into securities purchase agreements with certain institutional investors for the issuance and sale in a private placement of (i) 124,000 shares of the Company’s common stock, par value $0.0001 per share at a purchase price of $6.452 per Share; (ii) pre-funded warrants to… Filing
  7. Jun 18, 2026AnnouncementAs previously disclosed, on June 27, 2025, Silo Pharma, Inc. received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC indicating that, based upon the closing bid price of the Company’s common stock for the thirty (30) consecutive business days ended June 25, 2025… Filing
  8. Jun 3, 2026AnnouncementThe information contained in Item 5.03 of this report is incorporated herein by reference. Filing
  9. Jun 1, 2026AnnouncementSilo Pharma, Inc. today announced that it will effect a 1-for-15 reverse split of its issued and outstanding common stock with a concurrent proportionate reduction of its authorized common stock effective as of 4:01 p.m. Filing
  10. Apr 2, 2026AgreementSilo Pharma, Inc. entered into an asset purchase agreement with Many Ads Inc. Filing
  11. Feb 23, 2026AnnouncementThe Company issued a press release announcing that the Company’s Board of Directors approved a stock repurchase program authorizing the purchase of up to $1 million of the Company’s common stock. Filing
  12. Dec 29, 2025ListingAs previously disclosed in a Current Report on Form 8-K filed by Silo Pharma, Inc. on June 27, 2025, the Company received a notification from The Nasdaq Stock Market, LLC that it is not in compliance with the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2) for continued… Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Silo Pharma financials

Famous investors that hold SILO

2 of the 50 well-known investors we track reported holding SILO in their latest 13F filing. The largest position is Jim Simons's, worth $35.5K.

FundQuarterSharesValueOf portfolioChange
Jim Simons · Renaissance TechnologiesQ3 202623,500$35.5K0.0%New
Ken Griffin · Citadel AdvisorsQ3 202616,441$24.8K0.0%-2%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named SILO in the last 120 days.

FiledHolderFormStake
Nov 16, 2026Anson Funds Management LP13G6.6%
Nov 16, 2026Anson Funds Management LP13G6.6%
Nov 10, 2026Mitchell P. Kopin13G/A10.0%
Nov 10, 2026Mitchell P. Kopin13G/A10.0%

Questions about Silo Pharma, Inc. (SILO) stock

Are SILO insiders buying or selling?

In the last 12 months, SILO insiders reported 6 open-market purchases worth $7.7K and no sales. The latest trade was on Dec 15, 2025. See every trade.

What is the short interest in SILO?

As of Oct 30, 2026, 13,785 SILO shares were sold short, 0.9% of the shares outstanding, down 37.6% from the report before. At the average daily volume of 12,874 shares, buying them all back would take about 1.1 trading days (days to cover). See the history.

Which famous investors hold SILO?

2 of the 50 well-known investors we track reported SILO in their latest 13F filing, including Jim Simons, Ken Griffin. The largest position is worth $35.5K. See all holders.

Executive pay

Silo Pharma's chief executive was paid a total of $522K for the year ended Dec 31, 2025, down 17% from $630K the year before. In the last 12 months, Silo Pharma's executives and directors bought $7.7K of stock on the open market and sold none.

Chief executive, total pay$522KYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$499KThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$101KThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.